newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On September 1, 2026, the Compensation Committee of Praxis Precision Medicines' Board granted restricted stock unit awards for 11,535 shares to 66 new non-executive employees.
  • The grants were issued under the 2024 Inducement Plan as material inducements for employment in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan is exclusively used for equity awards to individuals who were not previously employed by Praxis or who returned after a bona fide break in employment.
  • The restricted stock units will vest in four equal annual installments contingent upon continued employment on each vesting date.
  • Praxis Precision Medicines is a CNS precision neuroscience biopharmaceutical company utilizing its Cerebrum™ small molecule platform Solidus™ ASO platform to develop therapies for neurological disorders.
  • The company maintains a diversified CNS portfolio with four late-stage product candidates across movement disorders epilepsy 857-702-9452.